Local Inhibition of Complement Improves Mesenchymal Stem Cell Viability and Function After Administration.

Area of Science:

• Immunology
• Regenerative Medicine
• Biotechnology

Background:

• Mesenchymal stem cell (MSC) therapies have shown limited success in clinical trials.
• MSCs activate the complement system via unknown mechanisms after infusion, leading to cell damage.
• N-glycolylneuraminic acid on MSCs contributes to complement activation.

Purpose of the Study:

• To identify factors contributing to complement activation by MSCs.
• To develop a method to improve MSC viability and function after infusion.
• To investigate heparin coating as a strategy to mitigate complement-mediated MSC damage.

Main Methods:

• Investigated the role of N-glycolylneuraminic acid in MSC complement activation.
• Developed a method to coat MSCs with heparin.
• Assessed the impact of heparin coating on MSC viability and function in vitro and after infusion.
• Evaluated the mechanism of heparin's protective effect, including complement inhibition and Factor H recruitment.

Main Results:

• Identified N-glycolylneuraminic acid incorporation during in vitro culture as a cause of MSC complement activation.
• Demonstrated that heparin coating of MSCs significantly improved their viability and function post-infusion.
• Showed that heparin coating directly inhibits complement activation and recruits Factor H to the MSC surface.

Conclusions:

• Cell-surface engineering of MSCs with heparin is a viable strategy to overcome complement-mediated damage.
• Heparin coating enhances MSC therapeutic potential by improving cell survival and function.
• This approach offers a straightforward method to improve the efficacy of current MSC-based therapies.